Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Breakthrough measles and mumps infections raise concerns about vaccine-induced immunity duration.
• The measles-mumps-rubella vaccine (MMR3) is being investigated as a way to enhance long-term protection.

Purpose of the Study:

• To compare antibody levels and decay rates after two doses (MMR2) versus three doses (MMR3) of the measles-mumps-rubella vaccine.
• To assess the impact of MMR3 on seroprotection against measles, mumps, and rubella.

Main Methods:

• Compared IgG antibody levels in 9-year-old children (MMR2) and young adults (18-25 years, MMR3).
• Analyzed blood samples for measles, mumps, and rubella antibody titers.
• Assessed antibody decay rates over time.

Main Results:

• MMR3 demonstrated antibody boosting for all three vaccine components (measles, mumps, rubella).
• MMR3 showed significantly lower antibody decay rates compared to MMR2.
• The most prominent antibody decline differences were observed for mumps and rubella components.

Conclusions:

• The findings suggest that MMR3 provides enhanced and potentially longer-lasting seroprotection.
• A third MMR dose may improve the durability of vaccine-induced immunity against measles, mumps, and rubella.